Benzinga | Jun 14, 2021 10:21AM EDT

Piper Sandler Maintains Overweight on Vertex Pharmaceuticals, Lowers Price Target to $261

Piper Sandler analyst Edward Tenthoff maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and lowers the price target from $347 to $261.